What is QP Release? The Qualified Person and Pharma Regulatory Support

A batch can be fully packed, fully tested, correctly labelled and sitting on a pallet in a licensed warehouse, and still be legally worthless. Until a Qualified Person has certified it, it is not a medicine that can be placed on the market. It is stock.

QP release is where every other strand of pharma regulatory support has to hold up at once. Analytical results, deviation investigations, supplier qualification, environmental monitoring and packaging records all converge on one named individual deciding whether a specific batch, identified by number, was made and tested in accordance with Good Manufacturing Practice and with the terms of its marketing authorisation.

This article explains who the QP is, what the role requires, what the QP actually reviews, and why QP capacity constrains commercial supply.

The Qualified Person is a legally named role

Under UK medicines legislation the QP is a statutory function, not a job title a company can hand out. Every manufacturer's and importer's authorisation (MIA) names the Qualified Persons attached to that site, and only a named QP can certify batches under it. Take the QP off the licence and the site loses the ability to release product, whatever else it can do.

Eligibility is defined rather than discretionary. A prospective QP needs an appropriate science degree, typically pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, or biology. They need practical experience, conventionally at least two years, in qualitative and quantitative analysis of active substances and in the testing necessary to assure the quality of medicinal products. They then have to satisfy an assessment run by the professional bodies, in the UK the Royal Pharmaceutical Society, the Royal Society of Biology and the Royal Society of Chemistry, covering law, GMP, quality systems and product knowledge.

The practical consequence is that QPs are not fungible. They cannot be recruited quickly, and a site with one QP has a single point of failure in its supply chain.

Certification and release are not the same thing

The two terms get used interchangeably and they should not be.

Certification is the QP's act: a confirmation, recorded in a register maintained under the MIA, that a named batch complies with GMP and with the marketing authorisation for its destination market. It attaches to the batch, and it is made by the individual, not the company.

Release is what happens afterwards. It is the quality and logistics act of moving the batch out of quarantine into saleable status so it can be despatched under a wholesale dealer's authorisation. Release without prior certification is a serious regulatory failure, and inspectors look hard at stock status controls for evidence of it.

The distinction matters because the two steps sit in different systems and sometimes different organisations. A contract packer may certify a batch that a marketing authorisation holder then releases into its own distribution model. The technical agreement should say plainly which party does which.

What the QP actually reviews

Certification is a documented judgement built on a defined evidence base. The QP works through:

• The batch manufacturing and batch packaging records, checked for completeness, in-process checks and reconciliation of components and finished units
• Deviations raised during manufacture and packing, with closed investigations and an assessment of product impact
• Out-of-specification and out-of-trend analytical results, with the investigation and any retest justification
• Analytical release data against the registered specification, including identity, assay and impurities
• Environmental and utility monitoring data covering the period of manufacture
• The supply chain of starting materials, including active substance and excipient source, and confirmation that each source is registered and qualified
• Validation and qualification status of the equipment, processes and cleaning used
• The artwork and labelling versions applied, checked against the approved product information for the destination market

Where the active substance is made outside the UK, there is also the QP declaration: a written confirmation, signed by or on behalf of the QP at the certifying site, that the active substance has been manufactured in accordance with GMP. It supports the marketing authorisation and has to be kept current as supply chains change.

Imported product and the site of importation

For product manufactured outside the UK, certification is the responsibility of the QP at the UK site of importation. That site must hold an MIA authorising importation, and the QP has to be satisfied the batch was made and tested to the registered standard, which may mean testing on importation unless an applicable arrangement permits reliance on the testing already done.

This is why Site of Importation and Site of QP Release carry commercial weight rather than just describing a building. They determine where product can lawfully enter the market and who can certify it. Central Pharma is both, and its three Qualified Persons release product to more than 60 countries.

Reliance on audits of third-country sites

A QP cannot personally inspect every site in a supply chain. What the role permits is documented reliance: audits of third-country manufacturers carried out by the site's own qualified auditors or by a competent third party under written agreement, with the report available to the QP and its scope, date and findings understood. Responsibility does not transfer with the audit. The QP still owns the decision, which is why those reports get read rather than filed.

Personal accountability and what happens when something is wrong

The QP carries personal legal and professional accountability. Certification is made in an individual's name, and a failure of that judgement can bring regulatory action against the person as well as the company, alongside professional sanction. That is deliberate. It creates someone with the standing to say no.

Saying no has a defined shape. A batch that cannot be certified stays in quarantine under physical and system control while the investigation runs. If the investigation resolves the question, certification proceeds with the rationale documented. If it does not, the batch is rejected and destroyed under controlled conditions. Where a problem emerges after certification, the route is recall, a GDP and MHRA notification process rather than a QP one.

Why pharma regulatory support is a capacity question

No certification, no market. That is the whole commercial argument. A batch that misses a QP slot misses its shipment, and against a tender date or a threatened stock-out that cost is immediate.

So ask any prospective partner how many QPs are named on the licence, how release is covered during holidays and illness, what the typical documentation review time is, and how deviations are escalated so they do not surface on the day certification is due.

Key takeaways

• The Qualified Person is a statutory role named on the MIA; only a named QP can certify batches under that licence.
• Certification is the QP's confirmation that a batch complies with GMP and the marketing authorisation; release is the separate act of moving it into saleable stock.
• The QP reviews batch and packaging records, deviations, OOS results, analytical data, environmental monitoring and the starting material supply chain before signing.
• For imported product, the QP at the UK site of importation certifies the batch, which is why importation and QP release status determine market access.
• QP capacity is a real supply chain constraint: an uncertified batch cannot be sold, whatever its physical condition.

Talk to Central Pharma about outsourced pharmaceutical logistics

Central Pharma is a Site of Importation and a Site of QP Release, with three Qualified Persons certifying product for more than 60 countries from its 267,000 sq ft Bedford site. Batch certification sits alongside primary filling, secondary packing, serialisation and dedicated project management under an MHRA MIA, WDA(H) and API storage licence, so the evidence a QP needs is generated in the same quality system that reviews it. If you need pharma regulatory support with QP capacity behind it, get in touch.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news